Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls.

By M. Unger, J. Spiegel, Klaus-Ulrich Dillmann, D. Grundmann, Hannah Philippeit, J. Bürmann, K. Fassbender, A. Schwiertz, K. Schäfer. Parkinsonism & Related Disorders, 2016

1,030 citations recorded by the source corpus.

Subfields: Molecular Biology, Neurology, Speech and Hearing

View Paper: https://www.semanticscholar.org/paper/2e08db402fd4b1c1f32c5c298fdfd7c8be543ec7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Neurology

Daniel H. Geschwind

Citations in the corpus

The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication (2020, result): “and Prevotellaceae in contrast to increased Enterobacteriaceae and reduced production of SCFAs when compared to matched controls (139).”
Parkinson’s Disease and PD Medications Have Distinct Signatures of the Gut Microbiome (2017, background): “Several studies have implicated depletion of short chain fatty acids (SCFA) in the pathogenesis of PD.10,12,14,35-37 SCFA is made by bacteria in the gut, notably Lachnospiraceae.”
The Central Nervous System and the Gut Microbiome (2016, result): “Interestingly, decreased SCFA concentrations in feces from PD patients, as compared to controls, were recently reported (Unger et al., 2016).”
Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease (2016, neutral): “Conversely, the gut microbiomes in human subjects with PD contain an increased abundance of Proteobacteria (Hasegawa et al., 2015; Keshavarzian et al., 2015; Scheperjans et al., 2015; Unger et al., 2016), remarkably similar to our results in mice.”
Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. (2018, background): “Growing evidence shows that alterations in gut microbiota composition and microbial metabolites may be involved in the pathogenesis and clinical phenotype of PD (Scheperjans et al., 2015; Unger et al., 2016).”
Short-chain fatty acids: linking diet, the microbiome and immunity (2024, neutral): “Individuals with Parkinson disease demonstrate reduced levels of butyrate and other SCFAs in the intestine 146 .”
Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis (2019, background): “Specifically, SCFAs induce proliferation of Foxp3+ Tregs via histone modifications, with increased acetylation and decreased deacetylation at Foxp3 promoter region [69, 70].”
The Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different Rates (2018, background): “Recent studies showed that PD is associated with gut dysbiosis (24, 170), the fecal concentration of short-chain fatty acids is significantly reduced in PD patients compared with controls, and this reduction could impact on CNS alterations and contribute to gastrointestinal dysmobility in PD (171).”